BS01 in Patients With Retinitis Pigmentosa

Description

Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).

Conditions

Retinitis Pigmentosa

Talk to us

Study Overview

On this page

Study Details

Study overview

Non-randomized, open label, Phase 1/2 dose escalation study of BS01, a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP).

Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP in Patients With Retinitis Pigmentosa

BS01 in Patients With Retinitis Pigmentosa

Condition
Retinitis Pigmentosa
Intervention / Treatment

-

Contacts and Locations

New York

OCLI, New York, New York, United States, 11572

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Confirmed diagnosis of retinitis pigmentosa
  • * Bare light perception in at least one eye
  • * Prior receipt of any AAV gene therapy product
  • * Large amplitude nystagmus

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bionic Sight LLC,

Sheila Nirenberg, PhD, STUDY_DIRECTOR, Bionic Sight LLC

Study Record Dates

2029-12-30